1. Home
  2. MNSB vs ACOG Comparison

MNSB vs ACOG Comparison

Compare MNSB & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MainStreet Bancshares Inc.

MNSB

MainStreet Bancshares Inc.

HOLD

Current Price

$20.53

Market Cap

148.8M

Sector

Finance

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$5.95

Market Cap

129.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNSB
ACOG
Founded
2003
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
148.8M
129.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MNSB
ACOG
Price
$20.53
$5.95
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
33.3K
65.6K
Earning Date
01-27-2026
11-13-2025
Dividend Yield
1.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$69,367,000.00
$7,427,199.00
Revenue This Year
$21.22
N/A
Revenue Next Year
$3.33
$132.35
P/E Ratio
N/A
N/A
Revenue Growth
9.71
N/A
52 Week Low
$15.00
$3.75
52 Week High
$22.98
$11.54

Technical Indicators

Market Signals
Indicator
MNSB
ACOG
Relative Strength Index (RSI) 53.40 46.67
Support Level $19.77 $5.20
Resistance Level $21.45 $6.04
Average True Range (ATR) 0.58 0.46
MACD 0.04 -0.06
Stochastic Oscillator 56.28 41.87

Price Performance

Historical Comparison
MNSB
ACOG

About MNSB MainStreet Bancshares Inc.

MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: